Skip to main content
SpringerLink
Log in

Galantamine vs Donepezil in the Treatment of Alzheimer’s Disease

  • Correspondence
  • Published:
Drugs & Aging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  1. Wilcock G, Howe I, Coles H, et al. A long-term comparison of galantamine and donepezil in the treatment of Alzheimer’s disease. Drugs Aging 2003; 20(10): 777–89

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Geriatric Medicine, University of Toronto, Toronto, Ontario, Canada

    Barry Goldlist, Michael Gordon & Gary Naglie

Authors
  1. Barry Goldlist
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Gordon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gary Naglie
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Goldlist, B., Gordon, M. & Naglie, G. Galantamine vs Donepezil in the Treatment of Alzheimer’s Disease. Drugs Aging 20, 1139–1140 (2003). https://doi.org/10.2165/00002512-200320150-00009

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200320150-00009

Keywords

Search

Navigation